Next Article in Journal
Does Hypoxia Cause Carcinogenic Iron Accumulation in Alcoholic Liver Disease (ALD)?
Previous Article in Journal
Roles of microRNAs and RNA-Binding Proteins in the Regulation of Colorectal Cancer Stem Cells
Previous Article in Special Issue
STAT3 but Not HIF-1α Is Important in Mediating Hypoxia-Induced Chemoresistance in MDA-MB-231, a Triple Negative Breast Cancer Cell Line
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessConference Report
Cancers 2017, 9(11), 146; doi:10.3390/cancers9110146

Advances in Precision Medicine: Tailoring Individualized Therapies

1
Centre for Cancer Research and Cell Biology, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
2
Department of Surgery, Trinity Translational Medicine Institute, Trinity College Dublin, College Green, Dublin 2, D08 W9RT, Ireland
3
School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, D04 V1W8, Ireland
4
Discipline of Surgery, School of Medicine, The Lambe Institute for Translational Research, National University of Ireland Galway, Galway H91 YR71, Ireland
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Zhixiang Wang
Received: 5 October 2017 / Revised: 18 October 2017 / Accepted: 19 October 2017 / Published: 25 October 2017
(This article belongs to the Special Issue Drug Resistance in Cancers)
View Full-Text   |   Download PDF [196 KB, uploaded 25 October 2017]

Abstract

The traditional bench-to-bedside pipeline involves using model systems and patient samples to provide insights into pathways deregulated in cancer. This discovery reveals new biomarkers and therapeutic targets, ultimately stratifying patients and informing cohort-based treatment options. Precision medicine (molecular profiling of individual tumors combined with established clinical-pathological parameters) reveals, in real-time, individual patient’s diagnostic and prognostic risk profile, informing tailored and tumor-specific treatment plans. Here we discuss advances in precision medicine presented at the Irish Association for Cancer Research Annual Meeting, highlighting examples where personalized medicine approaches have led to precision discovery in individual tumors, informing customized treatment programs. View Full-Text
Keywords: Ireland Cancer Meeting; personalized; PDX; avatar, precision medicine; profiling; Xenografts Ireland Cancer Meeting; personalized; PDX; avatar, precision medicine; profiling; Xenografts
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Matchett, K.B.; Lynam-Lennon, N.; Watson, R.W.; Brown, J.A.L. Advances in Precision Medicine: Tailoring Individualized Therapies. Cancers 2017, 9, 146.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top